Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing – OncLive
Posted: November 8, 2020 at 2:55 am
With the rise of actionable mutations in lung cancer, the role of molecular testing has become increasingly important, according to Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, and as more targeted agents emerge in the treatment landscape, the results from these tests must be used to inform clinical decisions.
Molecular testing to find a targetable mutation is already an important part of our daily practice. However, the process of finding these mutations may not be easy, said Mok. I believe we have a moral obligation to give it our best try. We need to obtain the best tissue or blood sample [that we can] and then use molecular testing to [identify] whether an oncogene driver [is present] so that we can select the appropriate treatment for each patient.
In an interview with OncLive, Mok, chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.
Mok: In the EGFR-mutant lung cancer space, we have 3 generations of therapies available. First-generation agents include erlotinib (Tarceva) and trametinib (Mekinist). Second-generation agents include afatinib (Gilotrif) and dacomitinib (Vizimpro). Finally, we have the third-generation agent, osimertinib. Each of these agents have their own set of special features; however, we now must determine whether there is one subgroup that may benefit more from one particular therapy than the others. For example, its understood that osimertinib may have superiority in patients who have brain metastases.
If there was an Oscar Award for the arena of lung cancer in 2020, then it would probably go to the ADAURA trial. This study was published in The New England Journal of Medicine and reported the use of osimertinib in the adjuvant setting for patients with resectable EGFR-mutant NSCLC.
The primary end point of the trial was disease-free survival (DFS) in patient with stage II/IIIa disease. There was a hazard ratio of 0.17. Now, with the DFS and impressive hazard ration, there is a reasonable chance that it may translate into an overall survival (OS) benefit.
I believe that every patient with resectable EGFR-mutant lung cancer should be informed about the study. The question of whether we should wait for OS data is debatable. However, the way I see it is, if a patient doesnt know about this [potential option], then they dont have a choice. What would happen if we do end up finding an OS benefit years later, but we had not informed our patients? This is an important study and our patients should be informed about it.
In the upcoming years, I believe that will be the focus of many efforts: the management of osimertinib (Tagrisso) resistance. As demonstrated during the 2020 ASCO Virtual Scientific Program and the 2020 ESMO Virtual Congress, there have been several exciting advancements.
For example, there is the use of bispecific antibodies that target both EGFR and MEK mutations. When [amivantamab (JNJ-61186372; JNJ-6372) was] used with lazertinib, there is a response rate of about 36%, which is encouraging for patients who have already [progressed on] osimertinib.
The other approach is to use an antibody-drug conjugate [ADC]. Another report from ESMO looked at the use of patritumab deruxtecan [U3-1402], which is an ADC that targets HER3; this agent also demonstrated a response of about 25%. I believe theres a lot of room for development when it comes to using different modalities to target patients who are resistant to osimertinib.
In terms of BRAF mutations, its quite standard to use the combination of trametinib and dabrafenib (Tafinlar) in patients with BRAF V600Epositive disease, either in the first- or second-line setting. [Its also important to remember the] resistance mechanism that has been reported [with this approach].
We have also seen exciting data in terms targeting ALK mutations. Two new compounds have been explored in phase 3 studies that turned out to be positive. For example, the CROWN study evaluated the role of first-line lorlatinib (Lorbrena), the central nervous system efficacy that we saw, and how the use of this agent compares with other second-generation TKIs.
With regard to ROS1, beyond crizotinib (Xalkori), theres entrectinib (Rozlytrek) and erlotinib. [We are examining] what the role of these agents will be in the management of ROS1-positive lung cancer.
Crizotinib was evaluated in about 50 patients who harbored ROS1 mutations, and we saw a high response rate of about 72% and a PFS of about 19 months. Stepping into the present, there are now additional studies to consider.
Lorlatinib was also able to target ROS1 and was included in the report by Benjamin Solomon, MD, of Peter MacCallum Cancer Centre, and colleagues, were also able to demonstrate a high efficacy, as well. Even after [progressing on] crizotinib, there was a response rate of over 30% [with this agent]. Entrectinib (Rozlytrek) is also used to ROS1 and has been associated with a high response rate.
BRAF V600E in a driver oncogene, which we know from melanoma. However, this could also occur in lung cancer, in about 3% of patients. Why V600E? Its because this transformation will add on to the growth signal that is actually controlled by the BRAF pathway. To adequately inhibit this [mutation, we needed] dual targeting.
As such, trametinib plus dabrafenib has been shown to be better than dabrafenib monotherapy. Now, [with this approach], there is an associated response rate of 60%, in the first- or second-line settings, and the median PFS is about 10 months. We should not miss the opportunity to identify a BRAF mutation, because patients can benefit from this inhibition.
Molecular testing has become a standard of care. The first target [that was discovered was] EGFR but, in a relatively short time, we were able to identify ALK and ROS1. As such, [those targets] have now become a part of daily practice, as well.
However, it doesn't stop there. There are also BRAF V600E and MET 14 skipping mutations. In the future, we could potentially target HER2, RET, and NTRK in this space. Instead of testing just one [mutation] at a time, we could test for all of them from the start.
There is still some debate around who should receive next-generation sequencing (NGS) early on; however, in the United States, its common for patients with lung cancer to undergo NGS from the start, before treatment initiation.
Read this article:
Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing - OncLive
- What is Genetic Cancer Testing and How Do Patients Get Tested? - Curetoday.com - January 9th, 2021
- Preimplantation Genetic Testing Market - Global Growth, Trends, and Forecast to 2025: Major Players are The Cooper Companies, Illumina, Thermo Fisher... - January 9th, 2021
- Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. - UroToday - January 9th, 2021
- Based on genes, nearly everyone is likely to have an atypical response to at least one drug - Scope - January 9th, 2021
- Color hits $1.5B valuation, plans to build on testing infrastructure - MedCity News - January 9th, 2021
- Preimplantation Genetic Testing Market Segments, Regional and Global Trends, Forecast and Competitive Landscape and Key Players -Inc. (US),... - January 9th, 2021
- Global Genetic Testing Market Forecasts for Applications and Technologies to 2025 - ResearchAndMarkets.com - Yahoo Finance - January 2nd, 2021
- Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer - DocWire News - January 2nd, 2021
- The Top 5 Most-Read Precision Oncology Articles of 2020 - AJMC.com Managed Markets Network - January 2nd, 2021
- Stock Markets Sink, but These 2020 Stock Winners Look Good for the New Year - The Motley Fool - January 2nd, 2021
- How to Make 2021 Your Healthiest Year Yet - Sarasota - January 2nd, 2021
- These Were the 5 Top Genetics Stocks of 2020 - Motley Fool - January 2nd, 2021
- Genetic Testing Services Market Research Report is Projected to Witness Considerable Growth by 2026 - Farming Sector - January 2nd, 2021
- Predictive Genetic Testing and Consumer/Wellness Genomics Market Rear Excessive Growth During 2017 to 2025 - Farming Sector - January 2nd, 2021
- Predictive Genetic Testing Market Size 2020, Global Trends, Industry Share, Growth Drivers, Business Opportunities and Demand Forecast to 2025 -... - January 2nd, 2021
- Preimplantation Genetic Testing Market Size, Share, Growth Trends, Revenue, Top Companies, Regional Outlook, and Forecast, 2020-2027 - LionLowdown - January 2nd, 2021
- San Diego County ends 2020 with largest single-day COVID-19 death total of the year - The San Diego Union-Tribune - January 2nd, 2021
- Direct Genetic Testing for Consumer Market is expected to show impressive growth rate between 2020 to 2026 - LionLowdown - January 2nd, 2021
- Hey, soldiers and spies think twice about that home genetic ancestry test - Roll Call - December 26th, 2020
- Population Testing for Hereditary Breast and Ovarian Cancer Worthwhile? - Medscape - December 26th, 2020
- $2 million settlement reached in lawsuit against ob-gyn office in Norwich - theday.com - December 26th, 2020
- Genetic Testing Market is Rapid Growing with COVID-19 Impact Analysis, Top Key Companies Abbott Laboratories, Bio-Rad Laboratories Inc., Competitive... - December 26th, 2020
- Toddler who received heart transplant due to get baby brother - Newsday - December 26th, 2020
- Impact of COVID-19 on Pre-Pregnancy Genetic Testing Market 2027 Expected to reach Highest CAGR - The Courier - December 26th, 2020
- DTC Genetic Testing Market Size By Type, By Application, By Geography, By Top Companies And Forecast To 2027 - LionLowdown - December 26th, 2020
- Breast Cancer Predictive Genetic Testing Market Likely to Experience a Tremendous Growth in Near Future|| Roche, Thermo Fisher Scientific,... - December 26th, 2020
- Prenatal Genetic Testing Market Key Trends, Strategic Indicators, Drivers, SWOT, Key Participants and Global Industry Overview and Key Players Natera... - December 24th, 2020
- Class action launched against Monash IVF over non-invasive embryo testing - ABC News - December 24th, 2020
- Science Talk - Being told I had the BRCA2 mutation effectively saved my life Tony's story - The - The Institute of Cancer Research - December 24th, 2020
- Predictive Genetic Testing Market Business Opportunities, Leading Players, Trends Outlook Up to 2025Agilent, Technologies, Inc., BGI Genomics,... - December 24th, 2020
- Publication Reveals in Side-by-Side Comparison that Method Using PacBio Sequencing Detects Only 72% of the Large Structural Variants Detected by... - December 24th, 2020
- Global DTC Genetic Testing Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier - December 24th, 2020
- Insights on the Genetic Testing Global Market (2021 to 2025) - Updated for COVID-19 Pandemic Impact - GlobeNewswire - December 22nd, 2020
- Researcher to test value of tailored gene testing - WA Health - December 22nd, 2020
- Latin American Patients with Lung Cancer and Native American Ancestry See Increased EGFR Mutations - Cancer Network - December 22nd, 2020
- 'For us, it was just an instant warm connection:' 5 siblings to unite for the first time - KXLH Helena News - December 22nd, 2020
- Preimplantation Genetic Testing Market 2020 Top Countries Market Analysis and Opportunity Assessment 2025 Research Report - Farming Sector - December 22nd, 2020
- 4 Women Share The Role Genetic Testing Played in Their Breast Cancer Treatment - Oprah Mag - December 21st, 2020
- Genetic Analysis Services Market: Uptake of Next-generation Sequencing and Multi-gene Tests to Drive Market - BioSpace - December 21st, 2020
- Clinical Utility of GBinsight Comprehensive Genetic Testing Showcased at the 2020 National Lipid Association's Scientific Sessions - PR Web - December 21st, 2020
- Moving Genomics to the Clinic - World Economic Forum - December 21st, 2020
- Sask. woman who got stomach removed to thwart cancer describes life with 'ticking time bomb' - CBC.ca - December 21st, 2020
- Elite Testing and Wellness Launches Innovative DNA Testing and IV Therapy in the Atlanta Market - PRNewswire - December 21st, 2020
- Oklahoma researchers looking for additional patients across the US with rare genetic mutation - KFOR Oklahoma City - December 21st, 2020
- Invitae: Network Strategy And Industry Tailwinds Should Offer Path To Profitability - Seeking Alpha - December 21st, 2020
- Reimagining mental healthcare from the ground up - Stanford Today - Stanford University News - December 21st, 2020
- A look at the diagnostics chapter of precision medicine - MedCity News - December 21st, 2020
- Illumina and Harvard Pilgrim Health Care Expand Access to Whole-Genome Sequencing for Genetic Disease Testing - Business Wire - December 9th, 2020
- Genetic disease in India: more prevalent than previously thought? - Hyderus Cyf - December 9th, 2020
- Point-of-Care Genetic Testing Market Size, Analysis, Regional Outlook, Competitive Strategies and Forecasts to 2027 - Cheshire Media - December 9th, 2020
- Local Announcement: Why I did Genetic Testing - NEW Breast of Everything Podcast - Patch.com - November 20th, 2020
- New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients - Yahoo Finance - November 20th, 2020
- Outlook on the Direct-to-Consumer Genetic Testing Global Market to 2025 - Featuring Genetic Technologies, Illumina & Myriad Genetics Among Others... - November 20th, 2020
- Direct-to-Consumer Genetic Testing: Global Markets and Technologies - GlobeNewswire - November 20th, 2020
- CancerIQ Officially Launches Lab Network to Increase Awareness and Accelerate Adoption of Genetic Testing - PR Web - November 20th, 2020
- Mayo Clinic study finds 1 in 8 patients with cancer harbor inherited genetic mutations - Greater Milwaukee Today - November 20th, 2020
- Small Covid Test Maker Is Going Viral - TheStreet - November 20th, 2020
- Genome Medical Reaches 90 Million Covered Lives in US - PRNewswire - November 20th, 2020
- Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors - Targeted Oncology - November 20th, 2020
- Global DTC Genetic Testing Market 2020 Comprehensive analysis with Top Manufacturers, Trends, Share, Future Growth Opportunities & Forecast by... - November 20th, 2020
- Global Preimplantation Genetic Testing Market Is Booming Globally | Most recent Report with Analysis | Future Possibility | Coronavirus Effect and... - November 20th, 2020
- Preimplantation Genetic Testing Market Outlook and Opportunities in Grooming Regions with Forecast to 2027 - The Daily Philadelphian - November 20th, 2020
- Genetic Testing Market by Size, Covid-19 Impact, Competitive Strategy, Worldwide Growth Insights, Regional Trends, Segmentation and Forecast to 2024 -... - November 20th, 2020
- Covid 19 Analysis On Direct-to-Consumer Genetic Testing Devices Market Growth in Business Future Scenarios and Brief Analysis of Top Key Players |... - November 20th, 2020
- Myriad Genetics Announces Global Expansion of Myriad myChoice Tumor Testing in Europe and China - GlobeNewswire - November 20th, 2020
- Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for... - November 10th, 2020
- Rare Disease Genetic Testing Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted... - November 10th, 2020
- The Value of a Molecular Diagnosis of Epilepsy - Medical Device and Diagnostics Industry - November 10th, 2020
- Pre-Pregnancy Genetic Testing Market : Drivers, Restraints, Opportunities, and Threats (20202025) - The Think Curiouser - November 10th, 2020
- The Implications of the Growing Role of Genetic TestingLecture by Anthropologist Rayna Rapp, Nov. 11 - NYU News - November 10th, 2020
- Global Preimplantation Genetic Testing Market: In-depth Analysis of Market Share, Size, Segmentaion, Top Players across the Region and Globe, Current... - November 10th, 2020
- Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis... - November 10th, 2020
- Preimplantation Genetic Testing Market Analysis, Size, Market Trends, Latest Technology and Cost Structures with Future Forecasts to 2027 - PRnews... - November 10th, 2020
- Increasing Government Investments and Favorable Policies to Aid the Growth of the Predictive Genetic Testing Market 2019 2029 - Eurowire - November 10th, 2020
- Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases - GlobeNewswire - November 10th, 2020
- Top Scenario: Direct-to-Consumer Genetic Testing Market 2020 to Witness Excellent Long-Term Growth Outlook Report by ResearchDive - The Think... - November 10th, 2020
- Dr. Rohs on the Importance of Genetic Testing in NSCLC - OncLive - November 8th, 2020
- Genetic Testing Can Lead to Precision Medicine Therapies for Cancer - HealthITAnalytics.com - November 8th, 2020
- One in Eight Cancer Patients Harbors Inherited Mutation that Increases Risk of Disease Development - Clinical OMICs News - November 8th, 2020
- How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial - DocWire... - November 8th, 2020